---
title: "Dyne Therapeutics, Inc. (DYN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DYN.US.md"
symbol: "DYN.US"
name: "Dyne Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T04:16:40.636Z"
locales:
  - [en](https://longbridge.com/en/quote/DYN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DYN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DYN.US.md)
---

# Dyne Therapeutics, Inc. (DYN.US)

## Company Overview

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.dyne-tx.com](https://www.dyne-tx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.82 | 395 | - | - | - |
| PB | 3.04 | 256 | 4.14 | 3.29 | 2.48 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 69% |
| Overweight | 3 | 19% |
| Hold | 2 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.92 |
| Highest Target | 50.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DYN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DYN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DYN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DYN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**